olmesartan has been researched along with Mucositis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brito, GA; Cavalcanti, Pde F; de Araújo, AA; de Araújo, RF; de Medeiros, CA; de Moura Freire, MA; Freire, MA; Reinaldo, MP | 1 |
| Araújo, TE; Borba, PB; da Silva, AI; de Araújo Júnior, RF; de Araújo, AA; de Souza, FH; Nogueira, AC; Saldanha, TS | 1 |
2 other study(ies) available for olmesartan and Mucositis
| Article | Year |
|---|---|
Olmesartan decreased levels of IL-1β and TNF-α, down-regulated MMP-2, MMP-9, COX-2, RANK/RANKL and up-regulated SOCs-1 in an intestinal mucositis model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Bacteremia; Cyclooxygenase 2; Cytokines; Disease Models, Animal; Down-Regulation; Imidazoles; Immunohistochemistry; Interleukin-1beta; Intestine, Small; Leukocytosis; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Methotrexate; Mucositis; RANK Ligand; Rats; Rats, Wistar; Receptor Activator of Nuclear Factor-kappa B; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins; Tetrazoles; Tumor Necrosis Factor-alpha; Up-Regulation | 2014 |
In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Diarrhea; Disease Models, Animal; Imidazoles; Inflammation; Interleukin-1beta; Intestinal Mucosa; Intestine, Small; Male; Methotrexate; Mucositis; Neoplasms; Olmesartan Medoxomil; Rats, Wistar; Sucrose; Tetrazoles; Tumor Necrosis Factor-alpha; Weight Loss | 2015 |